- Conditions
- Triple Negative Breast Cancer
- Interventions
- adagloxad simolenin combined with OBI-821, Globo H IHC Assay, Standard of care treatment
- Biological · Device · Other
- Lead sponsor
- OBI Pharma, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 575 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 12
- States / cities
- La Jolla, California • San Diego, California • San Francisco, California + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Metastatic Breast Cancer
- Interventions
- OPT-822/OPT-821(30 μg/100 μg), Phosphate Buffer Saline (PBS), Cyclophosphamide
- Biological · Drug
- Lead sponsor
- OBI Pharma, Inc
- Industry
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 349 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Fullerton, California • La Jolla, California + 10 more
- Conditions
- Solid Tumor, Pancreatic Adenocarcinoma
- Interventions
- OBI-3424
- Drug
- Lead sponsor
- OBI Pharma, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 5
- States / cities
- La Jolla, California • Los Angeles, California • New Brunswick, New Jersey + 2 more
- Conditions
- Advanced Solid Tumor
- Interventions
- OBI-902
- Drug
- Lead sponsor
- OBI Pharma, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 3
- States / cities
- La Jolla, California • Houston, Texas • San Antonio, Texas
- Conditions
- Advanced Solid Tumor
- Interventions
- OBI-992
- Drug
- Lead sponsor
- OBI Pharma, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 6
- States / cities
- Glendale, California • La Jolla, California • Detroit, Michigan + 3 more
- Conditions
- Metastatic Solid Tumors, Locally Advanced Solid Tumors
- Interventions
- OBI-888, Globo H IHC Assay
- Drug · Device
- Lead sponsor
- OBI Pharma, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 6
- States / cities
- La Jolla, California • Los Angeles, California • Newport Beach, California + 3 more
- Conditions
- Locally Advanced Solid Tumor
- Interventions
- OBI-999
- Drug
- Lead sponsor
- OBI Pharma, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 4
- States / cities
- La Jolla, California • New York, New York • Germantown, Tennessee + 1 more